Can a new immunotherapy combo tame aggressive appendiceal cancer?
NCT ID NCT07753824
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This phase II trial is testing whether combining the experimental immunotherapy drug ivonescimab with chemotherapy (paclitaxel) delivered directly into the abdomen can safely and effectively treat people with high-grade metastatic appendiceal adenocarcinoma that cannot be removed by surgery. The study will enroll about 30 adults who have had up to two prior lines of systemic therapy. Researchers will monitor side effects and look for signs that the treatment helps control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ivonescimab (an experimental immunotherapy drug) combined with paclitaxel (a chemotherapy drug) given directly into the abdomen
- What this could lead to
- If effective, this combination could offer a new treatment option for people with advanced appendiceal cancer, potentially slowing disease progression and improving outcomes.
- What could go wrong
- This is a small, early-phase study, so results may not be conclusive. The combination may cause side effects, and its benefit over standard treatments is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APPENDICEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink Hard-to-Treat adrenal tumors?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
- New drug combo aims to shrink oral cancers before surgery
- Blood test may predict nerve damage from common chemo drug
- Experimental shot takes aim at stomach cancer spread
- Supercharged t cells take on Hard-to-Treat cancers